A newly formed Irish-based biotechnology firm, TrinityBiotech plc, filed last week with the U.S. Securities an ExchangeCommission a registration for an initial public stock offering,according to Reuters news service.
Trinity's planned IPO is for the sale of 300,000 units, whicheach would consist of four American depository sharesrepresenting four common shares plus two class A and oneclass B stock purchase warrants.
The company was formed last January to acquire, develop andmarket rapid diagnostic tests for detecting AIDS, hepatitis andother sexually transmitted diseases.
(c) 1997 American Health Consultants. All rights reserved.